News & Updates

The next-generation ROS1 and TRK tyrosine kinase inhibitor (TKI) repotrectinib has demonstrated high response rates and durable activity in patients with ROS1 fusion–positive non-small-cell lung cancer (NSCLC), regardless of whether they have previously received ROS1 TKI therapy, according to phase II results of the ongoing registrational TRIDENT-1 trial.

Primary tumour resection (PTR) in combination with chemotherapy (C) appears beneficial to a specific subgroup of patients with unresectable colorectal mucinous adenocarcinoma with liver metastasis (UCR-MAC-LM) compared with PTR or C alone, suggests a study.

Restarting treatment with maintenance olaparib in ovarian cancer patients who had received one prior poly(ADP-ribose) polymerase (PARP) inhibitor and at least two lines of platinum-based chemotherapy results in a modest but significant improvement in progression-free survival (PFS) compared with placebo, results of a phase III study have shown.

Testicular cancer survivors (TCSs) demonstrate similar health-related quality of life (HRQoL) to that of the general population at a median of 28 years since treatment initiation, reports a study.

Breast cancer survivors who are at least 50 years of age appear to do well with less frequent mammographic surveillance, with survival outcomes being no worse than with annual mammograms, according to data from the phase III Mammo-50 trial.

For postmenopausal women with genomically defined low-risk stage I breast cancer who have been initiated on endocrine therapy immediately after breast-conserving surgery, the risk of recurrence is low despite the omission of radiation therapy, as shown in the IDEA* trial.

The addition of carfilzomib to lenalidomide and dexamethasone (KRd) improved outcomes in individuals with newly diagnosed fit or intermediate-fit multiple myeloma who are transplant ineligible (NTE NDMM) as opposed to Rd only in the phase III EMN20 trial.